No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BCRX240517P5000
- 0.05
- -0.03-37.50%
15min DelayClose May 13 15:49 ET
0.05High0.04Low
0.05Open0.08Pre Close137 Volume701 Open Interest5.00Strike Price598.00Turnover108.55%IV-12.08%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier4DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type-0.1409Delta0.3388Gamma112.60Leverage Ratio-0.0171Theta-0.0001Rho-15.86Eff Leverage0.0014Vega
Intraday
- 5D
- 1D
News
BioCryst Says Orladeyo Granted Approval in Mexico
BioCryst Pharmaceuticals (BCRX) said Monday that it has received approval for Orladeyo from Mexico's Federal Commission for Protection against Health Risks for the prophylaxis of hereditary angioedema
Express News | Orladeyo® (Berotralstat) Approved in Mexico
ORLADEYO (Berotralstat) Approved in Mexico
RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has
Here's What Analysts Are Forecasting For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its First-Quarter Results
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) just released its quarterly report and things are looking bullish. Revenues beat expectations coming in atUS$93m, ahead of estimates by 8.5%. Statutor
Express News | BioCryst Presents New Real-world Evidence Showing Significant Reductions In Healthcare Resource Utilization Among Patients With Hereditary Angioedema Following Initiation Of Orladeyo (Berotralstat)
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients With HAE Following Initiation of ORLADEYO (Berotralstat)
RESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO (berotralstat)
Comments
$BioCryst Pharmaceuticals(BCRX.US$ Benzinga· 1 min BioCryst Presents New Real-world Evidence Showing Significant Reductions In Healthcare Resource Utilization Among Patients With Hereditary Angioedema Following Initiation Of Orladeyo (Berotralstat
1
2
$BioCryst Pharmaceuticals(BCRX.US$ BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million—
—Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) —
—Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials—
—Q1 2024 ORLADEYO net revenue grows 30 percent y-o-y to $88.9 million—
—Full-year 2024 ORLADEYO revenue guidance adjusted to $390-$400 million (top end of prior guidance range) —
—Pipeline programs, including BCX17725 for Netherton syndrome and avoralstat for DME, advancing on schedule into clinical trials—
2
$BioCryst Pharmaceuticals(BCRX.US$
NEWS
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
NEWS
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
1
$BioCryst Pharmaceuticals(BCRX.US$ Still with the buy rating with a 12 PT!
1
Unprecedented HAE Attack Rate Reductions with ORLADEYO® (berotralstat): A Breakthrough in Medical Science.
BioCryst Pharmaceuticals, Inc., a leading American biotechnology company, has presented new real-world data that shows significant and sustained reductions in hereditary angioedema (HAE) attack rates after patients began treatment with ORLADEYO® (berotralstat). This groundbreaking development could have far-reaching imp...
BioCryst Pharmaceuticals, Inc., a leading American biotechnology company, has presented new real-world data that shows significant and sustained reductions in hereditary angioedema (HAE) attack rates after patients began treatment with ORLADEYO® (berotralstat). This groundbreaking development could have far-reaching imp...
1
Read more
Jaguar8 : This I like! Good for patients and healthcare institutions
TrytosaveabitOP Jaguar8: Yup yup!